Antonio Torrelo1, Ramon Grimalt2, Xavier Masramon3, Núria Albareda López4, Ilonka Zsolt5. 1. Department of Dermatology, Children's Hospital del Niño Jesús, Madrid, Spain. 2. Universitat Internacional de Catalunya, Barcelona, Spain. 3. SAIL (Servicio de Asesoría a la Investigación y Logística) SL, Barcelona, Spain. 4. Clinical Research Department, Ferrer Internacional SA, Barcelona, Spain. 5. Medical Department, Ferrer Internacional SA, Barcelona, Spain, izsolt@ferrer.com.
Abstract
BACKGROUND: Ozenoxacin is a topical antibiotic approved in Europe to treat non-bullous impetigo in adults and children aged ≥6 months. This analysis evaluated the efficacy and safety of ozenoxacin in paediatric patients by age group. METHODS: Pooled data for patients aged 6 months to <18 years who had participated in a phase I or in two phase III clinical trials of ozenoxacin 1% cream were analysed by age group: 0.5-<2, 2-<6, 6-<12, and 12-<18 years. RESULTS: The combined population comprised 529 patients with non-bullous impetigo treated with ozenoxacin (n = 239), vehicle (n = 201), or retapamulin as internal validation control (n = 89). Studies were well matched for extent and severity of impetigo and therapeutic schedule (twice daily application for 5 days). The clinical success rate after 5 days' treatment (day 6-7, end of therapy), and microbiological success rates after 3-4 days' treatment and at the end of therapy, were significantly higher with ozenoxacin than vehicle (p < 0.0001 for all comparisons). Clinical and bacterial eradication rates were higher with ozenoxacin than vehicle in each age group. No safety concerns were identified with ozenoxacin. One (0.3%) of 327 plasma samples exceeded the lower limit of quantification for ozenoxacin, but the low concentration indicated negligible systemic absorption. CONCLUSION: This combined analysis supports the efficacy and safety of ozenoxacin administered twice daily for 5 days. Ozenoxacin 1% cream is a new option to consider for treatment of non-bullous impetigo in children aged 6 months to <18 years. The Author(s). Published by S. Karger AG, Basel.
BACKGROUND:Ozenoxacin is a topical antibiotic approved in Europe to treat non-bullous impetigo in adults and children aged ≥6 months. This analysis evaluated the efficacy and safety of ozenoxacin in paediatric patients by age group. METHODS: Pooled data for patients aged 6 months to <18 years who had participated in a phase I or in two phase III clinical trials of ozenoxacin 1% cream were analysed by age group: 0.5-<2, 2-<6, 6-<12, and 12-<18 years. RESULTS: The combined population comprised 529 patients with non-bullous impetigo treated with ozenoxacin (n = 239), vehicle (n = 201), or retapamulin as internal validation control (n = 89). Studies were well matched for extent and severity of impetigo and therapeutic schedule (twice daily application for 5 days). The clinical success rate after 5 days' treatment (day 6-7, end of therapy), and microbiological success rates after 3-4 days' treatment and at the end of therapy, were significantly higher with ozenoxacin than vehicle (p < 0.0001 for all comparisons). Clinical and bacterial eradication rates were higher with ozenoxacin than vehicle in each age group. No safety concerns were identified with ozenoxacin. One (0.3%) of 327 plasma samples exceeded the lower limit of quantification for ozenoxacin, but the low concentration indicated negligible systemic absorption. CONCLUSION: This combined analysis supports the efficacy and safety of ozenoxacin administered twice daily for 5 days. Ozenoxacin 1% cream is a new option to consider for treatment of non-bullous impetigo in children aged 6 months to <18 years. The Author(s). Published by S. Karger AG, Basel.
Authors: Y López; M Tato; P Espinal; F Garcia-Alonso; D Gargallo-Viola; R Cantón; J Vila Journal: Antimicrob Agents Chemother Date: 2013-09-30 Impact factor: 5.191
Authors: Asha C Bowen; Antoine Mahé; Roderick J Hay; Ross M Andrews; Andrew C Steer; Steven Y C Tong; Jonathan R Carapetis Journal: PLoS One Date: 2015-08-28 Impact factor: 3.240
Authors: Evelien M E van Bijnen; W John Paget; Casper D J den Heijer; Ellen E Stobberingh; Cathrien A Bruggeman; François G Schellevis Journal: BMC Fam Pract Date: 2014-10-25 Impact factor: 2.497
Authors: James Lever; Florian Kreuder; Jason Henry; Andrew Hung; Pierre-Marie Allard; Robert Brkljača; Colin Rix; Aya C Taki; Robin B Gasser; Jan Kaslin; Donald Wlodkowic; Jean-Luc Wolfender; Sylvia Urban Journal: Mar Drugs Date: 2022-08-29 Impact factor: 6.085